

## Special Issue

# New Insights on the Hippo-YAP/TAZ-TEAD Pathway and Its Roles in Cancer

### Message from the Guest Editors

This Special Issue of *Cancers* will focus on emerging research on the Hippo-YAP/TAZ-TEAD pathway in cancer. Topics include but are not limited to targeting the function of YAP, TAZ, and TEADs in cancer; identification and/or targeting of novel upstream regulatory pathways or downstream target genes of YAP/TAZ-TEAD; identification of biomarkers or other readouts for YAP/TAZ-TEAD-dependent tumors; and studies focused on understanding how dysregulation of the Hippo-YAP/TAZ-TEAD pathway contributes to cancer development or progression. We look forward to receiving your contributions.

---

### Guest Editors

Dr. John M. Lamar

Department of Molecular and Cellular Physiology, Mail Code 8, Room ME-600B5, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA

Dr. Ajaybabu V. Pobbati

1. Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

2. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/132485](https://mdpi.com/si/132485)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)